Former Goldman VP Reveals Mysterious "Gold Bank" With Huge Upside Potential He says the gains in this should be far greater than just bullion or mining stocks. Some folks had the chance to see 995% the last time we shared this exact "bank". Most people know nothing about it (except the rich and elite).

PXMD Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 57.90%

Insider Buying (Last 12 Months): $0.00

Insider Selling (Last 12 Months): $40,461.04

PaxMedica Insider Trading History Chart

PaxMedica Share Price & Price History

^$0.32

▼ -0.05 (-13.62%)

As of 05/3/2024 01:00 AM ET

Days: 30 | 90 | 365

The asset beating inflation by 4x

From Colonial Metals | Ad

"Trump Loophole" Beats Inflation? Inflation has been out of control for years. Forcing you to work longer and harder for more money that is worth less. By using the "Trump Loophole", you can use a special retirement account to buy gold — and other precious metals — without taxes or penalties.

That's why we have released our Free Precious Metals Investment Guide that explains all the details

PaxMedica Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
1/29/2024	Howard J Weisman	CEO	Sell	372	$0.47	$174.84	37,675
1/29/2024	Karen Larochelle	Director	Sell	78	$0.48	$37.44	2,829
11/27/2023	Howard J Weisman	CEO	Sell	162	$1.03	$166.86	38,047
11/27/2023	John F Coelho	Director	Sell	12	$1.02	$12.24	4,642
11/27/2023	Michael Derby	Major Shareholder	Sell	185	$1.03	$190.55	25,650
10/27/2023	Howard J Weisman	CEO	Sell	473	$3.23	$1,527.79	38,208
10/27/2023	Michael Derby	Major Shareholder	Sell	539	$3.23	$1,740.97	25,833
10/27/2023	Zachary Rome	Director	Sell	958	$3.06	$2,931.48	16,317
8/30/2023	Howard J Weisman	CEO	Sell	1,325	$7.65	$10,136.25	38,682
8/30/2023	Zachary Rome	Director	Sell	282	$7.99	$2,253.18	17,275
8/28/2023	Howard J Weisman	CEO	Sell	705	$8.33	$5,872.65	40,572
8/28/2023	John F Coelho	Director	Sell	45	$8.84	$397.80	4,687
8/28/2023	Michael Derby	Major Shareholder	Sell	411	$8.33	$3,423.63	26,758
8/21/2023	Zachary Rome	Director	Sell	1,176	$9.86	$11,595.36	20,546
3/9/2023	Karen Larochelle	Director	Sell	19	$25.16	$478.04	2,495
3/9/2023	Michael Derby	Chairman	Sell	126	$24.31	$3,063.06	19,084
3/8/2023	Howard J Weisman	CEO	Sell	1,905	$24.82	$47,282.10	32,066
3/8/2023	Zachary Rome	COO	Sell	1,766	$24.99	$44,132.34	17,166
3/6/2023	Howard J Weisman	CEO	Sell	799	$29.24	$23,362.76	35,357
3/6/2023	Michael Derby	Chairman	Sell	813	$29.24	$23,772.12	20,100
3/6/2023	Zachary Rome	COO	Sell	797	$29.24	$23,304.28	20,311
3/2/2023	Howard J Weisman	CEO	Sell	687	$32.98	$22,657.26	37,058
3/2/2023	John F Coelho	Director	Sell	177	$32.81	$5,807.37	3,962
3/2/2023	Michael Derby	Chairman	Sell	617	$32.98	$20,348.66	22,029
3/2/2023	Zachary Rome	COO	Sell	761	$32.98	$25,097.78	21,885

The asset beating inflation by 4x

From Colonial Metals | Ad

That's why we have released our Free Precious Metals Investment Guide that explains all the details

SEC Filings (Institutional Ownership Changes) for PaxMedica (NASDAQ:PXMD)

4.90% of PaxMedica stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

PaxMedica, Inc., a clinical stage biopharmaceutical company, focuses on the development of anti-purinergic drug therapies for the treatment of disorders with intractable neurologic symptoms. Its lead product candidate is PAX-101 that is in Phase 3 clinical trials, an intravenous formulation of suramin for the treatment of autism spectrum disorder, myalgic encephalomyelitis/chronic fatigue syndrome, long COVID-19 syndrome, fragile X syndrome, human African trypanosomiasis (HAT), and fragile X-associated tremor/ataxia syndrome. The company is developing PAX-102, an intranasal formulation of suramin for neurologic indications, as well as other new chemical entities that are targeted and selective antagonists of purine receptor subtypes; and PAX-HAT-301 for the treatment of HAT. It has a research collaboration agreement with PolarMar Health for Phase II clinical trial in austism spectrum disorder for emodin, which retains the rights for PolarMar to develop and commercialize any non-prescription supplement form of the product, and for PaxMedica, Inc. to retain exclusive rights to develop and commercialize a highly purified form of emodin. The company was formerly known as Purinix Pharmaceuticals LLC and changed its name to PaxMedica, Inc. in April 2020. PaxMedica, Inc. was incorporated in 2018 and is based in Tarrytown, New York.

Today's Range

Now: $0.32

$0.26

$0.39

50 Day Range

MA: $0.62

$0.32

$0.84

52 Week Range

Now: $0.32

$0.26

$29.75

Volume

427,245 shs

Average Volume

1,829,256 shs

Market Capitalization

$2.37 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of PaxMedica?: PaxMedica's top insider shareholders include:
Howard J Weisman (CEO)
Michael Derby (Major Shareholder)
Michael Derby (Chairman)
Zachary Rome (COO)
Zachary Rome (Director)
John F Coelho (Director)
Karen Larochelle (Director)
Learn More about top insider investors at PaxMedica.

Gold Mania

From Stansberry Research | Ad

See his free reveal right here.